Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Tehran defends ship seizure as a legal action, but tensions continue in the Gulf - 2Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- 3What is the Insurrection Act? Can Trump really use the military to 'put an end' to Minneapolis ICE protests?
- 4The Best Cell phone Brands for Tech Aficionados
- 5How did Hugh Jackman nail his latest role? Sequins, tighty-whities and embracing 'zero embarrassment.'
- Australian State Triggers Emergency Powers Amid Fuel Crisis
- Email Promoting Instruments for Compelling Efforts
- Figure out How to Utilize Your Web based Advertising Degree to Break into the Tech Business
- 2 bright planets light up April evenings — here's where and when to look
- Best Wellness Tracker Keep You On target
- Tehran synagogue damaged by missile strike according to Iranian media
- A NASA spacecraft orbiting Mars may be dead
- When faith comes under fire: How Iran’s repression of religious minorities has increased
- Sixteen Kenyans missing in Russia after army recruitment
